Paul Harmatz, MD, on Harnessing Accelerated Approval for LSDs, Rare Disease Treatment Advancements

Commentary
Video

The pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed challenges in investigating therapies for rare diseases.

“It's a very difficult area for FDA for investigators for sponsors, and most of all, for the families and their kids are rapidly changing and going downhill... It’s very hard to to convince the investment world with all of these challenges, to stay with these drugs and try to move through [the approval process]. Hopefully, the use of a biomarker will encourage them. [The CAMPSIITE] study alone going forward will be a really tremendous breakthrough. It'll be the first neuropathic MPS [therapy] that reaches [an approval decision].”

Rare Disease Day, held on February 29, 2024, is dedicated to raising awareness and understanding for the millions of patients who live with rare disorders worldwide. The event aims to highlight patient voices and advocate for increased research and support to better manage and treat rare diseases.

CGTLive® spoke with Paul Harmatz, MD, pediatric gastroenterologist and professor in residence at University of California at San Francisco, about his work with investigating therapies for rare diseases, namely lysosomal storage diseases and mucopolysaccharidosis, and the value of the accelerated approval pathway to encourage drug development for rare diseases.

Harmatz serves as an investigator on REGENXBIO’s pivotal phase 1/2/3 CAMPSIITE clinical trial (NCT03566043) assessing RGX-121 in patients with severe neuronopathic central nervous disease in MPS type 2 (MPSII), also known as Hunter syndrome. The trial recently met its primary endpoint of reducing cerebrospinal fluid (CSF) levels of D2S6 compared with baseline (P = .00016) and seems set to be the first therapy for MPS to receive a regulatory decision.

REFERENCE
Harmatz P, Ficicioglu C, Giugliani R, et al. CAMPSIITE™ phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II). Presented at: 2024 WORLDSymposium; February 4-9; San Diego, California. Abstract #135
Recent Videos
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.